The use of chemotherapy in the treatment of advanced gastric and pancreas cancer Conference Paper
| Author: | Kelsen, D. |
| Title: | The use of chemotherapy in the treatment of advanced gastric and pancreas cancer |
| Conference Title: | The Community Approach to Salvage Therapy in the Treatment of Advanced Cancer |
| Abstract: | Patients with advanced adenocarcinomas of the stomach and pancreas have an exceptionally poor prognosis. Curative surgery in these patients is either impossible (metastatic disease) or exceedingly difficult (locally advanced tumors). In gastric cancer, single-agent chemotherapy with drugs like 5- fluorouracil (5-FU), mitomycin, doxorubicin, and cisplatin has achieved overall response rates of 19% to 30%; slightly higher response rates have been reported in single-arm trials of 5-FU-containing combinations. However, random assignment trials, with rare exceptions, failed to demonstrate a survival advantage for combination therapy. Overall survival in this disease remains poor. In pancreatic cancer, only modest activity has been demonstrated with single agents (response rates of 25% and 24% at best, respectively, with 5-FU and mitomycin), and combination chemotherapy has not yielded better results. Modest improvements in the palliation of locally advanced pancreatic cancer have been achieved by combining 5-FU with radiation therapy. New, more effective treatment strategies are clearly indicated for both gastric and pancreatic cancer. |
| Keywords: | cancer chemotherapy; controlled study; antibiotic agent; hydroxyurea; clinical trial; drug activity; review; cisplatin; doxorubicin; fluorouracil; advanced cancer; cancer combination chemotherapy; drug efficacy; treatment planning; antineoplastic agents; pancreas cancer; pancreatic neoplasms; methotrexate; neoplasm staging; cancer palliative therapy; adenocarcinoma; carboplatin; controlled clinical trial; phase 2 clinical trial; etoposide; randomized controlled trial; antineoplastic combined chemotherapy protocols; alkylating agent; carmustine; multicenter study; drug response; stomach cancer; epirubicin; phase 1 clinical trial; amsacrine; mitomycin; stomach adenocarcinoma; stomach neoplasms; clinical trials; chlorambucil; antimetabolite; mitoguazone; oral drug administration; tegafur; diaziquone; trimetrexate; uracil; bisantrene; razoxane; semustine; heavy metal; humans; human; priority journal; carmofur; triazinate |
| Journal Title | Seminars in Oncology |
| Volume: | 21 |
| Issue: | 4 Suppl. 7 |
| Conference Dates: | 1993 Jun 18-19 |
| ISBN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1994-08-01 |
| Start Page: | 58 |
| End Page: | 66 |
| Language: | English |
| PUBMED: | 8091242 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 February 2019 -- Source: Scopus |
